The BGM Galectin-3® Test

A recognized blood test that identifies patients with chronic heart failure who are at high risk of hospitalization or mortality.

Of the more than 1 million hospitalizations for heart failure (HF) annually, nearly 25% of these HF patients will be readmitted to the hospital during the fragile 30-day period after being discharged. Many of these patients will present with similar signs and symptoms.

The results of the BGM Galectin-3® Test may help identify patients with chronic HF who are clinically stable but at a higher risk of adverse events, including hospitalization and mortality.

This information allows Health Care Providers and hospitals to allocate scarce resources to those who need them the most, control unnecessary hospitalization costs and optimize care to ensure the right patient, gets the right care at the right time.

The BGM Galectin-3® Test is an in vitro diagnostic device that quantitatively measures galectin-3 in serum or plasma by enzyme linked immunosorbent assay (ELISA) on a microtiter plate platform, to be used in conjunction with clinical evaluation as an aid in assessing the prognosis of patients diagnosed with chronic heart failure. For full prescribing information, including warnings and precautions, please refer to the product insert.

About BG Medicine

BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, is dedicated to developing and delivering innovative solutions for healthcare providers that provide insight and transform the clinical care of heart failure and related disorders.